Boehringers new lung drug promises success for COPD

Pharmatimes has reported that Boehringer Ingelheim’s new lung drug tiotropium in the Phase III data trial significantly reduced exacerbations and improved both lung function and quality of life.

The results of the trial showed that the drug could cut the risk of severe asthma exacerbation by 21% in patients who remain symptomatic despite receiving treatment for the disease.

Sttudy author Professor Huib Kerstjens of the University Medical Centre, Groningen said “While we were anticipating improvements in lung function when adding tiotropium to usual care, the significant reduction in the risk of exacerbations came as a surprise – especially given that all patients were already receiving optimal maintenance treatment as defined by the GINA guidelines”


Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.


Posted in: Industry News, News
CK Logo in place of featured image